Fat ingestion is associated with increased levels of apoC-III- and apoE-B-containing lipoprotein particles in humans

European Journal of Clinical Investigation

Volumn 27, Issue 12, 1997, Pages 1055-1060

  Dallongeville, J ^a   Bauge E ^a   Lebel, P ^a   Fruchart, J C ^a  

^a INSTITUT PASTEUR DE LILLE   (France)

Author keywords

Apolipoprotein C III; Apolipoprotein E; Lipid; Lipoprotein; Nutrition; Very low density lipoprotein

Indexed keywords

APOLIPOPROTEIN B; APOLIPOPROTEIN C3; APOLIPOPROTEIN E;

ADULT; ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FAT INTAKE; HUMAN; HUMAN EXPERIMENT; HUMAN TISSUE; LIPOPROTEIN BLOOD LEVEL; LIPOPROTEIN METABOLISM; MALE; NORMAL HUMAN; PRIORITY JOURNAL;

EID: 0031467379     PISSN: 00142972     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2362.1997.2350782.x     Document Type: Article

References (28)

1. Alaupovic P. The lipoprotein family concept and its clinical significance. Nutr Metab Cardiovasc Dis 1992;2:52-4.
2. Alaupovic P. Apolipoprotein composition as the basis for classifying plasma lipoproteins. Characterization of apoA- and apoB-containing lipoprotein families. Prog Lipid Res 1991;30:105-38.
3. Kandoussi A, Cachera C, Parsy D, Bard JM, Fruchart JC. Quantitative determination of different apolipoprotein B containing lipoproteins by an enzyme linked immunosorbent assay: apo B with apo C-III and apo B with apo E. J Immunoassay 1991;12:305-23.
4. Bard JM, Candelier L, Agnani G et al. Isolation and characterization of human LpB lipoprotein containing apolipoprotein B as the sole apolipoprotein. Biochim Biophys Acta 1991;1082:170-6.
5. Fless GM, Rolick CA, Scanu AM. Heterogeneity of human plasma lipoprotein (a), Isolation and characterization of the lipoprotein subspecies and their apoproteins. J Biol Chem 1984;259:11470-8.
6. Bard JM, Delattre-Lestavel S, Clavey V et al. Isolation and characterization of two sub-species of Lp (a), one containing apo E and one free of apo E. Biochim Biophys Acta 1992;1127:124-30.
7. Lussier-Cacan S, Bard JM, Boulet L et al. Lipoprotein composition changes induced by fenofibrate in dysbetalipoproteinemia type III. Atherosclerosis 1989;78:167-82.
8. Alaupovic P, McConathy WJ, Fesmire J, Tavella M, Bard JM. Profiles of apolipoprotein B-containing lipoprotein particles in dyslipoproteinemias. Clin Chem 1988;34:B13-B27.
9. Wang CS, McConathy WJ, Kloer HU, Alaupovic P. Modulation of lipoprotein lipase activity by apolipoprotcins. Effect of apolipoprotein C-III. J Clin Invest 1985;75:384-90.
10. Agnani G, Bard JM, Candelier L, Delattre S, Fruchart JC, Clavey V. Interaction of LpB, LpB: E, LpC-III: B and LpB: C-III: E lipoproteins with the low density lipoprotein receptor on HeLa cells. Arteriosclerosis 1991;11:1021-9.
11. Clavey V, Lestavel-Delattre S, Copin C, Bard JM, Fruchart JC. Modulation of lipoprotein binding to the LDL receptor by exogenous lipids and apolipoproteins C-I, C-II, C-III, and E. Arterioscler Thromb Vasc Biol 1995;15:963-71.
12. Lipid Research Clinics Program. Manual of laboratory operations. Vol. 1. Lipid and lipoprotein analysis. Washington, DC: US Government Printing Office, 1974.
13. Traber MG, Kayden HJ, Rindler MJ. Polarized secretion of newly synthesized lipoproteins by Caco-2 human intestinal cell line. J Lipid Res 1987;28:1350-63.
14. Cohn JS, McNamara JR, Cohn SD, Ordovas JM, Schhaefer EJ. Plasma apolipoprotein changes in the triglyceride-rich lipoprotein fraction of human subjects led a fat-rich meal. J Lipid Res 1988;29:925-36.
15. Koga S, Yamanaga Y, Fujii S, Yamamoto K, Ibayashi H. Effects of oral and intravenous fat administration on the levels of apoproteins A-I, A-II and C-III in human subjects. Atherosclerosis 1982;41:115-24.
16. Thuren T, Wilcox RW, Sisson P, Waite M. Hepatic lipase hydrolysis of lipid monolayers. Regulation by apolipoproteins. J Biol Chem 1991;266:4853-61.
17. Kinnunen PKJ, Ehnholm C. Effect of serum and apoC-apoproteins from very low density lipoproteins on human postheparin plasma hepatic lipase. FEBS Lett 1976;65:354-7.
18. McConathy WJ, Gesquiere JC, Bass H, Tartar A, Fruchart JC, Wang CS. Inhibition of lipoprotein lipase activity by synthetic peptides of apolipoprotein C-III. J Lipid Res 1992;33:995-1003.
19. de Silva HV, Lauer SJ, Wang J et al. Overexpression of human apolipoprotein C-III in transgenic mice results in an accumulation of apolipoprotein B48 remnants that is corrected by excess apolipoprotein E. J Biol Chem 1994;3:2324-35.
20. Genest JJ, Bard JM, Fruchart JC, Ordovas JM, Wilson PFW, Schaeffer EJ. Plasma apolipoprotein A-I, A-II, B, E and C-III containing particles in men with premature coronary artery disease. Atherosclerosis 1991;90:149-57.
21. Alaupovic P, Blackenhorn DH, Knight-Gibson C et al. ApoB-containing lipoprotein particles as risk factors for coronary artery disease. Adv Exp Med Biol 1991;285:299-309.
22. Coste-Burel M, Mainard F, Chivot L, Auget JL, Madec Y. Study of lipoprotein particles LpAI and LpAI: AII in patients before coronary bypass surgery. Clin Chem 1990;36:1889-91.
23. Puchois P, Kandoussi A, Fievet P et al. Apolipoprotein A-I containing lipoproteins in coronary artery disease. Atherosclerosis 1987;68:35-40.
24. Amouyel P, Isorez D, Bard JM et al. Parental history of early myocardial infarction is associated with decreased levels of lipo-particle AI in adolescents. Arterioscler Thromb 1993;13:1640-4.
25. Parra HJ, Arveiller D, Evans AF, et al. A case-control study of lipoprotein particles in two populations at contrasting risk for coronary heart disease: the ECTIM study. Arterioscler Thromb 1992;12:701-7.
26. Blankenhorn DH, Alaupovic P, Wickham E, Chin HP, Azen SP. Prediction of angiographic change in native human coronary arteries and aortocoronary bypass grafts: lipid and non-lipid factors. Circulation 1990;81:470-6.
27. Hodis HN, Mack WJ, Azen SP et al. Triglyceride- and cholesterol-rich lipoproteins have a differential effect on mild/moderate and severe lesion progression as assessed by quantitative coronary angiography in a controlled trial of lovastatin. Circulation 1994;90:42-9.
28. Luc G, Fievet C, Arveiler D et al. Apolipoproteins C-III and E in apoB- and non-apoB-containing lipoproteins in two populations at contrasting risk for myocardial infarction: the ECTIM study. J Lipid Res 1996;37:508-17.